PE-VC Fund Investments
D2C nutraceuticals brand Zeroharm raises Rs.40-Cr from Kotak Alts
Hyderabad-based plant-based nutraceutical direct-to-consumer (D2C) brand Zeroharm Sciences has raised INR 40 Cr from Kotak Alternate Asset Managers Limited (Kotak Alts), through its Kotak Life Sciences Fund I (KLSF-I).Founded in 2020 by Sachin Darbarwar, Zeroharm Sciences offers nutraceuticals and ayurvedic supplements for immunity, joint health, skincare and gut health. The company operates with integrated in-house capabilities across botanical extraction, formulation research and development, and manufacturing. Its products are sold via its website, e-commerce marketplaces, and quick commerce platforms in India, with a presence in the USA, the UK, and the Middle East.The new funds will be used to accelerate scale-up operations, strengthen brand visibility, enhance customer loyalty, and support expansion into new domestic and international markets.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
